Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study from North France, apremilast was used in patients with psoriasis and recent cancer, showing a good safety profile and improved quality of life, though with 65.2% experiencing non-serious adverse events. The need for further research on oncological safety was highlighted.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study found that a polyherbal formulation of Trigonella foenum-graecum seeds and Butea monosperma flowers significantly promoted hair growth and reduced dihydrotestosterone levels in a chemotherapy-induced alopecia model.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This study found that the proposed LC-MS/MS method accurately quantified the drug content in split tablets of finasteride and terbinafine, revealing significant variability and suggesting that non-scored tablets should not be split.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

This study found that integrating Lactobacillus-rich probiotic nutrition and fractional CO₂ laser therapy with clotrimazole in mucoadhesive hydrogels significantly improved clinical and structural outcomes for women with recurrent vulvovaginal candidiasis, suggesting a promising advanced therapy, though further validation in larger trials is needed.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This review highlights brimonidine’s potential as a dermatological agent, noting its ability to improve rosacea-related facial redness and its effectiveness in various other skin conditions due to its vasoconstrictive and anti-inflammatory actions, with minimal systemic absorption and a favorable safety profile for long-term use.

This study developed and tested a finasteride suspension that retains over 94.3% of its initial concentration for up to 90 days at room temperature, finding no airborne finasteride exposure during formulation handling.

This study found that a substantial number of patients continued tamsulosin and/or finasteride unnecessarily after prostate surgery, with poor documentation and communication contributing to this issue.

This article reviews the potential for α-difluoromethylornithine to help control hair growth and prevent cancer, but it does not present new clinical results.

This study synthesized and evaluated five 6-mercaptopurine derivatives for anticancer activity against three cancer cell lines, detailing the promising results of compound 1.

In this case report, the researchers highlighted the diagnostic challenge of Majocchi’s granuloma, a deep fungal infection that mimics other skin conditions and resists initial treatment, emphasizing the importance of considering it as a diagnosis even after failed topical antifungal therapies.

This study found that finasteride alone is highly effective in preventing Candida albicans urinary biofilms and shows synergistic activity with fluconazole in vitro, suggesting potential for further clinical investigation.

This study suggests that sirolimus and propranolol may reduce abnormal lymphatic endothelial cell proliferation in lymphatic malformations, potentially improving vessel function and patient outcomes.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

This study suggests that Breezula® and Minoxidil both enhance hair growth in male pattern hair loss by promoting keratinocyte proliferation, with Breezula® potentially more potent in reducing the hair growth inhibitor IL-6.

A woman with a rare autoimmune disorder had a blister on her eye and unique immune reaction, which was effectively treated with medication.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This study found that baicalin delivery through polymeric nanocapsules significantly enhanced its anticancer activity in breast cancer cell lines MCF-7 and MDA-MB-231.

This study suggests that combining monoammonium glycyrrhizinate/glycine/DL-methionine tablets with 5% carpronium chloride may reduce alopecia areata area more effectively than carpronium chloride alone, particularly in patients with allergic factors.

This study found that compounded minoxidil solutions in a propylene glycol-free and alcohol-reduced foam remained stable for 180 days, meeting United States Pharmacopeia standards for strength, pH, and antimicrobial effectiveness.

This review discusses ongoing and past trials for novel acne treatments, focusing on topical agents with potential sebosuppressive, antimicrobial, or anti-inflammatory effects, without reporting new clinical results.

This study reports that the monoclonal antibody BKN-1 specifically stained basal cell epithelioma cells and certain normal skin structures, indicating a similarity in keratin expression between the tumor and follicular epithelium below the isthmus portion.